Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (1746)	4/25/2001 5:16:58 PM
From: Glenn Petersen	Respond to of 3202

INCY beats the estimates on the loss side: biz.yahoo.com Wednesday April 25, 4:25 pm Eastern Time Incyte posts smaller-than-expected Q1 loss PALO ALTO, Calif., April 25 (Reuters) - Incyte Genomics Inc. (NasdaqNM:INCY - news), which develops databases of genetic information used by drug and biotech companies, on Wednesday posted a 25-percentjump in first-quarter revenues and a net loss that beat Wall Street forecasts. Incyte posted a net loss of $10.3 million, or 16 cents a diluted share, compared with a loss of $8.2 million, or 13 cents, in the year-earlier quarter. The company's revenues rose 25 percent to $51.1 million from $40.8 million in the same 2000 quarter. Wall Street analysts expected a per-share loss of 20 cents to 31 cents, with estimates averaging 28 cents, according to Thomson Financial/First Call. Incyte said revenues generated by its database and partnership program reached $37 million in the first quarter while custom genomics revenues were $14.1 million.

To: LLCF who wrote (1746)	4/26/2001 2:41:22 PM
From: RCMac	Read Replies (2) \| Respond to of 3202

Motley Fool belatedly works out that INCY might have a more attractive business plan than CRA: fool.com Excerpt: "In short, here's what Celera asks investors to believe: That it's somehow got better drug discovery and development information and tools, will extract better and bigger deals from big pharma, and will make more money on its own than companies like Incyte and HGS that are years ahead in the same game." More importantly, there is a link to a February interview with INCY CEO Roy Whitfield (which I believe was discussed here earlier). Maybe Motley Fool is the reason for the 12% rise in INCY so far today? Motley Fool's raving about CRA in December(?), 1999 was one thing that set off the genomics stocks mania of the first quarter last year. --RCM